84 related articles for article (PubMed ID: 15725480)
1. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529.
Segawa H; Kimura S; Kuroda J; Sato K; Nogawa M; Yuasa T; Yokota A; Hodohara K; Fujiyama Y; Maekawa T
Leuk Res; 2005 Apr; 29(4):451-7. PubMed ID: 15725480
[TBL] [Abstract][Full Text] [Related]
2. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
5. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Sato K; Yuasa T; Nogawa M; Kimura S; Segawa H; Yokota A; Maekawa T
Br J Cancer; 2006 Nov; 95(10):1354-61. PubMed ID: 17043684
[TBL] [Abstract][Full Text] [Related]
6. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
7. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate.
Nakajima H; Magae J; Tsuruga M; Sakaguchi K; Fujiwara I; Mizuta M; Sawai K; Yamagishi H; Mizuta N
Cancer Lett; 2007 Aug; 253(1):89-96. PubMed ID: 17316980
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
9. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines.
Nishida S; Kikuichi S; Haga H; Yoshioka S; Tsubaki M; Fujii K; Irimajiri K
Biol Pharm Bull; 2003 Jan; 26(1):96-100. PubMed ID: 12520182
[TBL] [Abstract][Full Text] [Related]
11. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
Horie N; Murata H; Nishigaki Y; Matsui T; Segawa H; Nogawa M; Yuasa T; Kimura S; Maekawa T; Fushiki S; Kubo T
Cancer Lett; 2006 Jul; 238(1):111-8. PubMed ID: 16112430
[TBL] [Abstract][Full Text] [Related]
12. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
[TBL] [Abstract][Full Text] [Related]
13. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
15. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
17. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
18. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
20. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
